Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

PDMR Dealing

25 Mar 2020 12:42

RNS Number : 5784H
Oncimmune Holdings PLC
25 March 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Meinhard Schmidt, PDMR and Non-Executive Chairman, has purchased 18,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for 49 pence per share on 24 March 2020.

 

Following this transaction, Meinhard has a total interest in the Company of 18,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's issued Ordinary Share capital.  

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Meinhard Schmidt

2

 

Reason for the notification

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£0.49

18,000

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Same as above

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

24 March 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

contact@oncimmune.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKKPBQBBKDDNB
Date   Source Headline
28th Apr 20257:00 amRNSCancellation - ONCIMMUNE HOLDINGS PLC
26th Mar 202512:45 pmRNSAppointment of Administrators & Nomad Resignation
19th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:30 amRNSSuspension - Oncimmune Holdings Plc
17th Mar 20257:00 amRNSIntention to Appoint Administrators and Suspension
14th Mar 20257:00 amRNSBlock Listing Return
10th Mar 20251:39 pmRNSResult of GM
27th Feb 20254:18 pmRNSResult of AGM
24th Feb 20257:00 amRNSStrategic update
18th Feb 20257:00 amRNSHolding(s) in Company
12th Feb 20257:01 amRNSBlock Listing Return
12th Feb 20257:00 amRNSPosting of Notice of General Meeting
10th Feb 20257:00 amRNSFinal Results
4th Feb 202510:38 amRNSHolding(s) in Company
3rd Feb 20257:00 amRNSNotice of Annual General Meeting
31st Jan 20257:00 amRNSTrading Update
10th Dec 20243:36 pmRNSHolding(s) in Company
4th Dec 20241:38 pmRNSHolding(s) in Company
13th Nov 20245:06 pmRNSHolding(s) in Company
13th Nov 202411:41 amRNSHolding(s) in Company
12th Nov 20245:17 pmRNSHolding(s) in Company
12th Nov 20244:49 pmRNSHolding(s) in Company
11th Nov 202411:15 amRNSDirector/PDMR Shareholding
8th Nov 20242:37 pmRNSResults of General Meeting and Total Voting Rights
31st Oct 20245:07 pmRNSResult of Retail Offer
31st Oct 20247:00 amRNSTrading Update
23rd Oct 20244:12 pmRNSPosting of Circular and Notice of General Meeting
18th Oct 20243:05 pmRNSResult of Placing & Issue of Equity
18th Oct 20248:00 amRNSRetail Offer
18th Oct 20247:47 amRNSFundraising and Amendments to Facility
9th Sep 20247:00 amRNSTrading Update
2nd Sep 20247:00 amRNSContract Win
9th Aug 20247:00 amRNSUS$1.5m Contract Win with Top 10 Pharma Company
24th Jun 202411:18 amRNSHolding(s) in Company
17th Jun 20242:30 pmRNSHolding(s) in Company
29th May 20245:45 pmRNSHolding(s) in Company
21st May 20247:00 amRNSInterim Results
17th May 202410:11 amRNSInvestor Presentation via Investor Meet Company
9th May 20243:08 pmRNSHolding(s) in Company
26th Apr 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
25th Apr 202410:44 amRNSHolding(s) in Company
2nd Apr 202411:34 amRNSResult of General Meeting
2nd Apr 20248:00 amRNSTotal Voting Rights
26th Mar 202411:18 amRNSHolding(s) in Company
13th Mar 20245:32 pmRNSBlock Listing Return
6th Mar 20243:02 pmRNSPosting of Notice of General Meeting
1st Mar 20241:00 pmRNSInvestor Presentation via Investor Meet Company
29th Feb 202411:19 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFinal Results
26th Feb 202411:30 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.